#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=Coronaviruses ( CoVs ) are single-strand plus RNA viruses , which belong to the order Nidovirales .
3-1	17-30	Coronaviruses	object	new	_	_
3-2	31-32	(	_	_	_	_
3-3	33-37	CoVs	abstract	new	coref	4-1
3-4	38-39	)	_	_	_	_
3-5	40-43	are	_	_	_	_
3-6	44-57	single-strand	_	_	_	_
3-7	58-62	plus	_	_	_	_
3-8	63-66	RNA	object|object[6]	new|new[6]	_	_
3-9	67-74	viruses	object[6]	new[6]	_	_
3-10	75-76	,	_	_	_	_
3-11	77-82	which	_	_	_	_
3-12	83-89	belong	_	_	_	_
3-13	90-92	to	_	_	_	_
3-14	93-96	the	person[8]	new[8]	_	_
3-15	97-102	order	abstract|person[8]	new|new[8]	_	_
3-16	103-114	Nidovirales	person[8]	new[8]	_	_
3-17	115-116	.	_	_	_	_

#Text=CoVs normally infect epithelial cells such as respiratory epithelial cells , intestinal epithelial cells and kidney epithelial cells , which causes respiratory or intestinal tract diseases with various levels of severity .
4-1	117-121	CoVs	abstract	giv	coref	17-22[138_0]
4-2	122-130	normally	_	_	_	_
4-3	131-137	infect	_	_	_	_
4-4	138-148	epithelial	place[10]	new[10]	_	_
4-5	149-154	cells	place[10]	new[10]	_	_
4-6	155-159	such	place[10]	new[10]	_	_
4-7	160-162	as	place[10]	new[10]	_	_
4-8	163-174	respiratory	place[10]|place[12]	new[10]|new[12]	_	_
4-9	175-185	epithelial	place[10]|object|place[12]	new[10]|new|new[12]	coref	4-13
4-10	186-191	cells	place[10]|place[12]	new[10]|new[12]	_	_
4-11	192-193	,	place[10]	new[10]	_	_
4-12	194-204	intestinal	place[10]|place[14]	new[10]|new[14]	_	_
4-13	205-215	epithelial	place[10]|object|place[14]	new[10]|giv|new[14]	coref	4-17
4-14	216-221	cells	place[10]|place[14]	new[10]|new[14]	_	_
4-15	222-225	and	place[10]	new[10]	_	_
4-16	226-232	kidney	place[10]|place[16]	new[10]|new[16]	coref	17-36[141_16]
4-17	233-243	epithelial	place[10]|object|place[16]	new[10]|giv|new[16]	_	_
4-18	244-249	cells	place[10]|place[16]	new[10]|new[16]	_	_
4-19	250-251	,	_	_	_	_
4-20	252-257	which	_	_	_	_
4-21	258-264	causes	_	_	_	_
4-22	265-276	respiratory	abstract[18]	new[18]	_	_
4-23	277-279	or	abstract[18]	new[18]	_	_
4-24	280-290	intestinal	abstract[18]	new[18]	_	_
4-25	291-296	tract	object|abstract[18]	new|new[18]	_	_
4-26	297-305	diseases	abstract[18]	new[18]	_	_
4-27	306-310	with	_	_	_	_
4-28	311-318	various	abstract[19]	new[19]	_	_
4-29	319-325	levels	abstract[19]	new[19]	_	_
4-30	326-328	of	abstract[19]	new[19]	_	_
4-31	329-337	severity	abstract[19]|abstract	new[19]|new	_	_
4-32	338-339	.	_	_	_	_

#Text=Human coronavirus 229E ( HCoV-229E ) is a main cause of the common cold , while severe acute respiratory syndrome coronavirus ( SARS-CoV ) and Middle East respiratory syndrome coronavirus ( MERS-CoV ) cause severe respiratory disease that can be life-threatening to humans .
5-1	340-345	Human	abstract[22]	new[22]	coref	5-8[24_22]
5-2	346-357	coronavirus	plant|abstract[22]	new|new[22]	coref	5-17[27_0]
5-3	358-362	229E	abstract[22]	new[22]	_	_
5-4	363-364	(	_	_	_	_
5-5	365-374	HCoV-229E	object	new	_	_
5-6	375-376	)	_	_	_	_
5-7	377-379	is	_	_	_	_
5-8	380-381	a	abstract[24]	giv[24]	_	_
5-9	382-386	main	abstract[24]	giv[24]	_	_
5-10	387-392	cause	abstract[24]	giv[24]	_	_
5-11	393-395	of	abstract[24]	giv[24]	_	_
5-12	396-399	the	abstract[24]	giv[24]	_	_
5-13	400-406	common	abstract[24]	giv[24]	_	_
5-14	407-411	cold	abstract[24]	giv[24]	_	_
5-15	412-413	,	_	_	_	_
5-16	414-419	while	_	_	_	_
5-17	420-426	severe	plant[27]	giv[27]	coref	7-4[0_27]
5-18	427-432	acute	plant[27]	giv[27]	_	_
5-19	433-444	respiratory	abstract|plant[27]	new|giv[27]	_	_
5-20	445-453	syndrome	event|plant[27]	new|giv[27]	coref	5-29
5-21	454-465	coronavirus	plant[27]	giv[27]	_	_
5-22	466-467	(	_	_	_	_
5-23	468-476	SARS-CoV	abstract	new	coref	18-7
5-24	477-478	)	_	_	_	_
5-25	479-482	and	_	_	_	_
5-26	483-489	Middle	place[29]	new[29]	_	_
5-27	490-494	East	place[29]	new[29]	_	_
5-28	495-506	respiratory	_	_	_	_
5-29	507-515	syndrome	event	giv	_	_
5-30	516-527	coronavirus	_	_	_	_
5-31	528-529	(	_	_	_	_
5-32	530-538	MERS-CoV	abstract	new	coref	18-62
5-33	539-540	)	_	_	_	_
5-34	541-546	cause	_	_	_	_
5-35	547-553	severe	abstract[32]	new[32]	coref	9-18[66_32]
5-36	554-565	respiratory	abstract[32]	new[32]	_	_
5-37	566-573	disease	abstract[32]	new[32]	_	_
5-38	574-578	that	_	_	_	_
5-39	579-582	can	_	_	_	_
5-40	583-585	be	_	_	_	_
5-41	586-602	life-threatening	_	_	_	_
5-42	603-605	to	_	_	_	_
5-43	606-612	humans	person	new	_	_
5-44	613-614	.	_	_	_	_

#Text=However , some CoVs-like mouse hepatitis virus John Howard Mueller strain ( MHV-JHM ) infect oligodendrocytes , astrocytes and microglia and cause acute encephalomyelitis .
6-1	615-622	However	_	_	_	_
6-2	623-624	,	_	_	_	_
6-3	625-629	some	abstract[37]|person[38]	new[37]|new[38]	coref|coref	9-1[62_37]|9-1[62_37]
6-4	630-639	CoVs-like	abstract|abstract[37]|person[38]	new|new[37]|new[38]	_	_
6-5	640-645	mouse	animal|abstract[37]|person[38]	new|new[37]|new[38]	_	_
6-6	646-655	hepatitis	abstract|abstract[37]|person[38]	new|new[37]|new[38]	_	_
6-7	656-661	virus	abstract[37]|person[38]	new[37]|new[38]	_	_
6-8	662-666	John	abstract[37]|person[38]	new[37]|new[38]	_	_
6-9	667-673	Howard	abstract[37]|person[38]	new[37]|new[38]	_	_
6-10	674-681	Mueller	_	_	_	_
6-11	682-688	strain	_	_	_	_
6-12	689-690	(	_	_	_	_
6-13	691-698	MHV-JHM	abstract	new	_	_
6-14	699-700	)	_	_	_	_
6-15	701-707	infect	_	_	_	_
6-16	708-724	oligodendrocytes	person	new	_	_
6-17	725-726	,	_	_	_	_
6-18	727-737	astrocytes	object	new	_	_
6-19	738-741	and	_	_	_	_
6-20	742-751	microglia	object	new	_	_
6-21	752-755	and	_	_	_	_
6-22	756-761	cause	_	_	_	_
6-23	762-767	acute	abstract[43]	new[43]	_	_
6-24	768-785	encephalomyelitis	abstract[43]	new[43]	_	_
6-25	786-787	.	_	_	_	_

#Text=Additionally , human coronavirus OC43 ( HCoV-OC43 ) can also reach the central nervous system ( CNS ) by intranasal inoculation in BALB/c mice , which causes encephalitis .
7-1	788-800	Additionally	_	_	_	_
7-2	801-802	,	_	_	_	_
7-3	803-808	human	object[45]	new[45]	appos	7-7[0_45]
7-4	809-820	coronavirus	plant|object[45]	giv|new[45]	_	_
7-5	821-825	OC43	object[45]	new[45]	_	_
7-6	826-827	(	_	_	_	_
7-7	828-837	HCoV-OC43	object	giv	_	_
7-8	838-839	)	_	_	_	_
7-9	840-843	can	_	_	_	_
7-10	844-848	also	_	_	_	_
7-11	849-854	reach	_	_	_	_
7-12	855-858	the	place[47]	new[47]	_	_
7-13	859-866	central	place[47]	new[47]	_	_
7-14	867-874	nervous	place[47]	new[47]	_	_
7-15	875-881	system	place[47]	new[47]	_	_
7-16	882-883	(	_	_	_	_
7-17	884-887	CNS	place	new	_	_
7-18	888-889	)	_	_	_	_
7-19	890-892	by	_	_	_	_
7-20	893-903	intranasal	event[49]	new[49]	_	_
7-21	904-915	inoculation	event[49]	new[49]	_	_
7-22	916-918	in	event[49]	new[49]	_	_
7-23	919-925	BALB/c	event[49]|animal|animal[51]	new[49]|new|new[51]	_	_
7-24	926-930	mice	event[49]|animal[51]	new[49]|new[51]	_	_
7-25	931-932	,	_	_	_	_
7-26	933-938	which	_	_	_	_
7-27	939-945	causes	_	_	_	_
7-28	946-958	encephalitis	abstract	new	coref	8-22
7-29	959-960	.	_	_	_	_

#Text=The release of cytokines such as TNF-α , interleukin-1β ( IL-1β ) and interleukin-6 ( IL-6 ) is closely associated with encephalitis .
8-1	961-964	The	event[53]	new[53]	_	_
8-2	965-972	release	event[53]	new[53]	_	_
8-3	973-975	of	event[53]	new[53]	_	_
8-4	976-985	cytokines	event[53]|abstract[54]	new[53]|new[54]	_	_
8-5	986-990	such	event[53]|abstract[54]	new[53]|new[54]	_	_
8-6	991-993	as	event[53]|abstract[54]	new[53]|new[54]	_	_
8-7	994-999	TNF-α	event[53]|abstract[54]|abstract	new[53]|new[54]|new	_	_
8-8	1000-1001	,	event[53]|abstract[54]	new[53]|new[54]	_	_
8-9	1002-1016	interleukin-1β	event[53]|abstract[54]|object	new[53]|new[54]|new	appos	8-11
8-10	1017-1018	(	event[53]|abstract[54]	new[53]|new[54]	_	_
8-11	1019-1024	IL-1β	event[53]|abstract[54]|object	new[53]|new[54]|giv	_	_
8-12	1025-1026	)	event[53]|abstract[54]	new[53]|new[54]	_	_
8-13	1027-1030	and	event[53]|abstract[54]	new[53]|new[54]	_	_
8-14	1031-1044	interleukin-6	event[53]|abstract[54]|abstract	new[53]|new[54]|new	appos	8-16
8-15	1045-1046	(	_	_	_	_
8-16	1047-1051	IL-6	abstract	giv	_	_
8-17	1052-1053	)	_	_	_	_
8-18	1054-1056	is	_	_	_	_
8-19	1057-1064	closely	_	_	_	_
8-20	1065-1075	associated	_	_	_	_
8-21	1076-1080	with	_	_	_	_
8-22	1081-1093	encephalitis	abstract	giv	_	_
8-23	1094-1095	.	_	_	_	_

#Text=Infectious bronchitis virus ( IBV ) belongs to the gamma-coronavirus group ( γ-CoV ) , which causes a highly contagious , acute viral respiratory disease of chickens that has caused great economic losses in the poultry industry .
9-1	1096-1106	Infectious	abstract[62]	giv[62]	appos	9-5[0_62]
9-2	1107-1117	bronchitis	person|abstract[62]	new|giv[62]	_	_
9-3	1118-1123	virus	abstract[62]	giv[62]	_	_
9-4	1124-1125	(	_	_	_	_
9-5	1126-1129	IBV	abstract	giv	coref	19-3
9-6	1130-1131	)	_	_	_	_
9-7	1132-1139	belongs	_	_	_	_
9-8	1140-1142	to	_	_	_	_
9-9	1143-1146	the	abstract[64]	new[64]	appos	9-13[0_64]
9-10	1147-1164	gamma-coronavirus	abstract[64]	new[64]	_	_
9-11	1165-1170	group	abstract[64]	new[64]	_	_
9-12	1171-1172	(	_	_	_	_
9-13	1173-1178	γ-CoV	abstract	giv	_	_
9-14	1179-1180	)	_	_	_	_
9-15	1181-1182	,	_	_	_	_
9-16	1183-1188	which	_	_	_	_
9-17	1189-1195	causes	_	_	_	_
9-18	1196-1197	a	abstract[66]	giv[66]	_	_
9-19	1198-1204	highly	abstract[66]	giv[66]	_	_
9-20	1205-1215	contagious	abstract[66]	giv[66]	_	_
9-21	1216-1217	,	abstract[66]	giv[66]	_	_
9-22	1218-1223	acute	abstract[66]	giv[66]	_	_
9-23	1224-1229	viral	abstract[66]	giv[66]	_	_
9-24	1230-1241	respiratory	abstract[66]	giv[66]	_	_
9-25	1242-1249	disease	abstract[66]	giv[66]	_	_
9-26	1250-1252	of	abstract[66]	giv[66]	_	_
9-27	1253-1261	chickens	abstract[66]|animal	giv[66]|new	coref	10-21
9-28	1262-1266	that	_	_	_	_
9-29	1267-1270	has	_	_	_	_
9-30	1271-1277	caused	_	_	_	_
9-31	1278-1283	great	abstract[68]	new[68]	_	_
9-32	1284-1292	economic	abstract[68]	new[68]	_	_
9-33	1293-1299	losses	abstract[68]	new[68]	_	_
9-34	1300-1302	in	abstract[68]	new[68]	_	_
9-35	1303-1306	the	abstract[68]|abstract[70]	new[68]|new[70]	ana	10-10[0_70]
9-36	1307-1314	poultry	abstract[68]|animal|abstract[70]	new[68]|new|new[70]	coref	25-17[204_0]
9-37	1315-1323	industry	abstract[68]|abstract[70]	new[68]|new[70]	_	_
9-38	1324-1325	.	_	_	_	_

#Text=At present , QX-type IBV is epidemic worldwide ; it can damage the respiratory , digestive and urogenital systems of chickens .
10-1	1326-1328	At	_	_	_	_
10-2	1329-1336	present	time	new	_	_
10-3	1337-1338	,	_	_	_	_
10-4	1339-1346	QX-type	place[72]	new[72]	coref	10-7[73_72]
10-5	1347-1350	IBV	place[72]	new[72]	_	_
10-6	1351-1353	is	_	_	_	_
10-7	1354-1362	epidemic	place[73]	giv[73]	coref	21-27[185_73]
10-8	1363-1372	worldwide	place[73]	giv[73]	_	_
10-9	1373-1374	;	_	_	_	_
10-10	1375-1377	it	abstract	giv	_	_
10-11	1378-1381	can	_	_	_	_
10-12	1382-1388	damage	_	_	_	_
10-13	1389-1392	the	object[75]	new[75]	_	_
10-14	1393-1404	respiratory	object[75]	new[75]	_	_
10-15	1405-1406	,	object[75]	new[75]	_	_
10-16	1407-1416	digestive	object[75]	new[75]	_	_
10-17	1417-1420	and	object[75]	new[75]	_	_
10-18	1421-1431	urogenital	object[75]	new[75]	_	_
10-19	1432-1439	systems	object[75]	new[75]	_	_
10-20	1440-1442	of	object[75]	new[75]	_	_
10-21	1443-1451	chickens	object[75]|animal	new[75]|giv	coref	11-11[79_0]
10-22	1452-1453	.	_	_	_	_

#Text=Besides , because of severe damage of respiratory mucosa , infected chickens are susceptible to secondary infection by mycoplasma , bacteria , or other pathogens causing high mortality .
11-1	1454-1461	Besides	_	_	_	_
11-2	1462-1463	,	_	_	_	_
11-3	1464-1471	because	_	_	_	_
11-4	1472-1474	of	_	_	_	_
11-5	1475-1481	severe	abstract[77]	new[77]	_	_
11-6	1482-1488	damage	abstract[77]	new[77]	_	_
11-7	1489-1491	of	abstract[77]	new[77]	_	_
11-8	1492-1503	respiratory	abstract[77]|object[78]	new[77]|new[78]	_	_
11-9	1504-1510	mucosa	abstract[77]|object[78]	new[77]|new[78]	_	_
11-10	1511-1512	,	_	_	_	_
11-11	1513-1521	infected	animal[79]	giv[79]	_	_
11-12	1522-1530	chickens	animal[79]	giv[79]	_	_
11-13	1531-1534	are	_	_	_	_
11-14	1535-1546	susceptible	_	_	_	_
11-15	1547-1549	to	_	_	_	_
11-16	1550-1559	secondary	abstract[80]	new[80]	_	_
11-17	1560-1569	infection	abstract[80]	new[80]	_	_
11-18	1570-1572	by	abstract[80]	new[80]	_	_
11-19	1573-1583	mycoplasma	abstract[80]|object	new[80]|new	_	_
11-20	1584-1585	,	abstract[80]	new[80]	_	_
11-21	1586-1594	bacteria	abstract[80]|animal	new[80]|new	_	_
11-22	1595-1596	,	abstract[80]	new[80]	_	_
11-23	1597-1599	or	abstract[80]	new[80]	_	_
11-24	1600-1605	other	abstract[80]|abstract[83]	new[80]|new[83]	_	_
11-25	1606-1615	pathogens	abstract[80]|abstract[83]	new[80]|new[83]	_	_
11-26	1616-1623	causing	_	_	_	_
11-27	1624-1628	high	abstract[84]	new[84]	_	_
11-28	1629-1638	mortality	abstract[84]	new[84]	_	_
11-29	1639-1640	.	_	_	_	_

#Text=All CoV virions encode a set of four structural proteins , namely ; spike glycoprotein ( S ) , small envelope protein ( E ) , membrane glycoprotein ( M ) and nucleocapsid proteins ( N ) .
12-1	1641-1644	All	animal[86]	new[86]	_	_
12-2	1645-1648	CoV	abstract|animal[86]	new|new[86]	_	_
12-3	1649-1656	virions	animal[86]	new[86]	_	_
12-4	1657-1663	encode	_	_	_	_
12-5	1664-1665	a	substance[87]	new[87]	_	_
12-6	1666-1669	set	substance[87]	new[87]	_	_
12-7	1670-1672	of	substance[87]	new[87]	_	_
12-8	1673-1677	four	substance[87]	new[87]	_	_
12-9	1678-1688	structural	substance[87]	new[87]	_	_
12-10	1689-1697	proteins	substance[87]	new[87]	_	_
12-11	1698-1699	,	_	_	_	_
12-12	1700-1706	namely	substance[89]	new[89]	coref	12-27[95_89]
12-13	1707-1708	;	substance[89]	new[89]	_	_
12-14	1709-1714	spike	object|substance[89]	new|new[89]	coref	16-20
12-15	1715-1727	glycoprotein	substance[89]	new[89]	_	_
12-16	1728-1729	(	_	_	_	_
12-17	1730-1731	S	abstract	new	coref	15-1
12-18	1732-1733	)	_	_	_	_
12-19	1734-1735	,	_	_	_	_
12-20	1736-1741	small	substance[92]	new[92]	coref	13-1[100_92]
12-21	1742-1750	envelope	object|substance[92]	new|new[92]	_	_
12-22	1751-1758	protein	substance[92]	new[92]	_	_
12-23	1759-1760	(	_	_	_	_
12-24	1761-1762	E	person	new	_	_
12-25	1763-1764	)	_	_	_	_
12-26	1765-1766	,	_	_	_	_
12-27	1767-1775	membrane	object|substance[95]	new|giv[95]	coref|coref	14-1[108_95]|14-1[108_95]
12-28	1776-1788	glycoprotein	substance[95]	giv[95]	_	_
12-29	1789-1790	(	_	_	_	_
12-30	1791-1792	M	abstract	new	_	_
12-31	1793-1794	)	_	_	_	_
12-32	1795-1798	and	_	_	_	_
12-33	1799-1811	nucleocapsid	abstract|substance[98]	new|new[98]	coref|coref	13-7[104_98]|13-7[104_98]
12-34	1812-1820	proteins	substance[98]	new[98]	_	_
12-35	1821-1822	(	_	_	_	_
12-36	1823-1824	N	person	new	_	_
12-37	1825-1826	)	_	_	_	_
12-38	1827-1828	.	_	_	_	_

#Text=S protein belongs to the class I fusion proteins , located at the surface of the virion .
13-1	1829-1830	S	substance[100]	giv[100]	coref	14-10[0_100]
13-2	1831-1838	protein	substance[100]	giv[100]	_	_
13-3	1839-1846	belongs	_	_	_	_
13-4	1847-1849	to	_	_	_	_
13-5	1850-1853	the	person[101]	new[101]	_	_
13-6	1854-1859	class	person[101]	new[101]	_	_
13-7	1860-1861	I	person|substance[104]	acc|giv[104]	_	_
13-8	1862-1868	fusion	abstract|substance[104]	new|giv[104]	coref	17-15
13-9	1869-1877	proteins	substance[104]	giv[104]	_	_
13-10	1878-1879	,	_	_	_	_
13-11	1880-1887	located	_	_	_	_
13-12	1888-1890	at	_	_	_	_
13-13	1891-1894	the	place[105]	new[105]	_	_
13-14	1895-1902	surface	place[105]	new[105]	_	_
13-15	1903-1905	of	place[105]	new[105]	_	_
13-16	1906-1909	the	place[105]|object[106]	new[105]|new[106]	_	_
13-17	1910-1916	virion	place[105]|object[106]	new[105]|new[106]	_	_
13-18	1917-1918	.	_	_	_	_

#Text=The trimeric S glycoprotein is a class I fusion protein and mediates attachment to the host receptor .
14-1	1919-1922	The	abstract[108]	giv[108]	coref	14-6[109_108]
14-2	1923-1931	trimeric	person[107]|abstract[108]	new[107]|giv[108]	_	_
14-3	1932-1933	S	person[107]|abstract[108]	new[107]|giv[108]	_	_
14-4	1934-1946	glycoprotein	abstract[108]	giv[108]	_	_
14-5	1947-1949	is	_	_	_	_
14-6	1950-1951	a	abstract[109]	giv[109]	_	_
14-7	1952-1957	class	abstract[109]	giv[109]	_	_
14-8	1958-1959	I	person	acc	_	_
14-9	1960-1966	fusion	_	_	_	_
14-10	1967-1974	protein	substance	giv	coref	16-9[124_0]
14-11	1975-1978	and	_	_	_	_
14-12	1979-1987	mediates	_	_	_	_
14-13	1988-1998	attachment	event	new	_	_
14-14	1999-2001	to	_	_	_	_
14-15	2002-2005	the	substance[114]	new[114]	_	_
14-16	2006-2010	host	person|substance[114]	new|new[114]	_	_
14-17	2011-2019	receptor	substance[114]	new[114]	_	_
14-18	2020-2021	.	_	_	_	_

#Text=S is typically cleaved by a host cell furin-like protease into two separate polypeptides named S1 and S2 .
15-1	2022-2023	S	person	giv	coref	16-10
15-2	2024-2026	is	_	_	_	_
15-3	2027-2036	typically	_	_	_	_
15-4	2037-2044	cleaved	_	_	_	_
15-5	2045-2047	by	_	_	_	_
15-6	2048-2049	a	animal[117]	new[117]	_	_
15-7	2050-2054	host	animal[117]	new[117]	_	_
15-8	2055-2059	cell	place|animal[117]	new|new[117]	coref	20-24
15-9	2060-2070	furin-like	animal[117]	new[117]	_	_
15-10	2071-2079	protease	animal[117]	new[117]	_	_
15-11	2080-2084	into	_	_	_	_
15-12	2085-2088	two	object[118]	new[118]	_	_
15-13	2089-2097	separate	object[118]	new[118]	_	_
15-14	2098-2110	polypeptides	object[118]	new[118]	_	_
15-15	2111-2116	named	_	_	_	_
15-16	2117-2119	S1	abstract	new	coref	16-1
15-17	2120-2123	and	_	_	_	_
15-18	2124-2126	S2	place	new	coref	16-14
15-19	2127-2128	.	_	_	_	_

#Text=S1 makes up the large receptor-binding domain of the S protein , while S2 forms the stalk of the spike molecule .
16-1	2129-2131	S1	abstract	giv	_	_
16-2	2132-2137	makes	_	_	_	_
16-3	2138-2140	up	_	_	_	_
16-4	2141-2144	the	abstract[122]	new[122]	_	_
16-5	2145-2150	large	abstract[122]	new[122]	_	_
16-6	2151-2167	receptor-binding	abstract[122]	new[122]	_	_
16-7	2168-2174	domain	abstract[122]	new[122]	_	_
16-8	2175-2177	of	abstract[122]	new[122]	_	_
16-9	2178-2181	the	abstract[122]|substance[124]	new[122]|giv[124]	coref	25-4[202_124]
16-10	2182-2183	S	abstract[122]|person|substance[124]	new[122]|giv|giv[124]	_	_
16-11	2184-2191	protein	abstract[122]|substance[124]	new[122]|giv[124]	_	_
16-12	2192-2193	,	_	_	_	_
16-13	2194-2199	while	_	_	_	_
16-14	2200-2202	S2	abstract	giv	coref	17-19
16-15	2203-2208	forms	_	_	_	_
16-16	2209-2212	the	plant[126]	new[126]	_	_
16-17	2213-2218	stalk	plant[126]	new[126]	_	_
16-18	2219-2221	of	plant[126]	new[126]	_	_
16-19	2222-2225	the	plant[126]|object[128]	new[126]|new[128]	_	_
16-20	2226-2231	spike	plant[126]|object|object[128]	new[126]|giv|new[128]	_	_
16-21	2232-2240	molecule	plant[126]|object[128]	new[126]|new[128]	_	_
16-22	2241-2242	.	_	_	_	_

#Text=There is an extra furin cleavage site ( furin-S2′ site ) upstream of the fusion peptide in the S2 subunit of some CoVs , which has been reported to influence the mechanism of invasion of host cells by CoVs .
17-1	2243-2248	There	_	_	_	_
17-2	2249-2251	is	_	_	_	_
17-3	2252-2254	an	organization[131]	new[131]	appos	17-9[132_131]
17-4	2255-2260	extra	organization[131]	new[131]	_	_
17-5	2261-2266	furin	person|organization[131]	new|new[131]	_	_
17-6	2267-2275	cleavage	person|organization[131]	new|new[131]	_	_
17-7	2276-2280	site	organization[131]	new[131]	_	_
17-8	2281-2282	(	_	_	_	_
17-9	2283-2292	furin-S2′	organization[132]	giv[132]	coref	18-28[151_132]
17-10	2293-2297	site	organization[132]	giv[132]	_	_
17-11	2298-2299	)	_	_	_	_
17-12	2300-2308	upstream	place[133]	new[133]	_	_
17-13	2309-2311	of	place[133]	new[133]	_	_
17-14	2312-2315	the	place[133]|substance[135]	new[133]|new[135]	_	_
17-15	2316-2322	fusion	place[133]|abstract|substance[135]	new[133]|giv|new[135]	_	_
17-16	2323-2330	peptide	place[133]|substance[135]	new[133]|new[135]	_	_
17-17	2331-2333	in	place[133]	new[133]	_	_
17-18	2334-2337	the	place[133]|abstract[137]	new[133]|new[137]	_	_
17-19	2338-2340	S2	place[133]|abstract|abstract[137]	new[133]|giv|new[137]	_	_
17-20	2341-2348	subunit	place[133]|abstract[137]	new[133]|new[137]	_	_
17-21	2349-2351	of	place[133]|abstract[137]	new[133]|new[137]	_	_
17-22	2352-2356	some	place[133]|abstract[137]|abstract[138]	new[133]|new[137]|giv[138]	coref	17-39[0_138]
17-23	2357-2361	CoVs	place[133]|abstract[137]|abstract[138]	new[133]|new[137]|giv[138]	_	_
17-24	2362-2363	,	_	_	_	_
17-25	2364-2369	which	_	_	_	_
17-26	2370-2373	has	_	_	_	_
17-27	2374-2378	been	_	_	_	_
17-28	2379-2387	reported	_	_	_	_
17-29	2388-2390	to	_	_	_	_
17-30	2391-2400	influence	_	_	_	_
17-31	2401-2404	the	abstract[139]	new[139]	_	_
17-32	2405-2414	mechanism	abstract[139]	new[139]	_	_
17-33	2415-2417	of	abstract[139]	new[139]	_	_
17-34	2418-2426	invasion	abstract[139]|event[140]	new[139]|new[140]	_	_
17-35	2427-2429	of	abstract[139]|event[140]	new[139]|new[140]	_	_
17-36	2430-2434	host	abstract[139]|event[140]|place[141]	new[139]|new[140]|giv[141]	coref	18-16[148_141]
17-37	2435-2440	cells	abstract[139]|event[140]|place[141]	new[139]|new[140]|giv[141]	_	_
17-38	2441-2443	by	abstract[139]|event[140]|place[141]	new[139]|new[140]|giv[141]	_	_
17-39	2444-2448	CoVs	abstract[139]|event[140]|place[141]|object	new[139]|new[140]|giv[141]|giv	_	_
17-40	2449-2450	.	_	_	_	_

#Text=When the original sequence PTKR/S of SARS-CoV was replaced with RRKR/S , SARS-CoV could invade susceptible cells while no longer relying on cathepsin L. Additionally , after the S2′ site mutated into the furin-S2′ site of the MHV-A59 strain , MHV can fuse with susceptible cells in the early endosome , but not lysosome , without requiring lysosomal enzymes such as MERS-CoV .
18-1	2451-2455	When	_	_	_	_
18-2	2456-2459	the	abstract[143]|abstract[144]	new[143]|new[144]	_	_
18-3	2460-2468	original	abstract[143]|abstract[144]	new[143]|new[144]	_	_
18-4	2469-2477	sequence	abstract[143]|abstract[144]	new[143]|new[144]	_	_
18-5	2478-2484	PTKR/S	abstract[144]	new[144]	_	_
18-6	2485-2487	of	abstract[144]	new[144]	_	_
18-7	2488-2496	SARS-CoV	abstract[144]|abstract	new[144]|giv	_	_
18-8	2497-2500	was	_	_	_	_
18-9	2501-2509	replaced	_	_	_	_
18-10	2510-2514	with	_	_	_	_
18-11	2515-2521	RRKR/S	abstract	new	_	_
18-12	2522-2523	,	_	_	_	_
18-13	2524-2532	SARS-CoV	person	new	_	_
18-14	2533-2538	could	_	_	_	_
18-15	2539-2545	invade	_	_	_	_
18-16	2546-2557	susceptible	place[148]	giv[148]	coref	18-45[157_148]
18-17	2558-2563	cells	place[148]	giv[148]	_	_
18-18	2564-2569	while	_	_	_	_
18-19	2570-2572	no	_	_	_	_
18-20	2573-2579	longer	_	_	_	_
18-21	2580-2587	relying	_	_	_	_
18-22	2588-2590	on	_	_	_	_
18-23	2591-2600	cathepsin	object[149]	new[149]	_	_
18-24	2601-2603	L.	object[149]	new[149]	_	_
18-25	2604-2616	Additionally	_	_	_	_
18-26	2617-2618	,	_	_	_	_
18-27	2619-2624	after	_	_	_	_
18-28	2625-2628	the	organization[151]	giv[151]	coref	18-33[153_151]
18-29	2629-2632	S2′	abstract|organization[151]	new|giv[151]	_	_
18-30	2633-2637	site	organization[151]	giv[151]	_	_
18-31	2638-2645	mutated	_	_	_	_
18-32	2646-2650	into	_	_	_	_
18-33	2651-2654	the	organization[153]	giv[153]	coref	19-5[165_153]
18-34	2655-2664	furin-S2′	abstract|organization[153]	new|giv[153]	coref	19-6
18-35	2665-2669	site	organization[153]	giv[153]	_	_
18-36	2670-2672	of	organization[153]	giv[153]	_	_
18-37	2673-2676	the	organization[153]|abstract[155]	giv[153]|new[155]	coref	19-15[169_155]
18-38	2677-2684	MHV-A59	organization[153]|abstract|abstract[155]	giv[153]|new|new[155]	_	_
18-39	2685-2691	strain	organization[153]|abstract[155]	giv[153]|new[155]	_	_
18-40	2692-2693	,	_	_	_	_
18-41	2694-2697	MHV	abstract	new	_	_
18-42	2698-2701	can	_	_	_	_
18-43	2702-2706	fuse	_	_	_	_
18-44	2707-2711	with	_	_	_	_
18-45	2712-2723	susceptible	place[157]	giv[157]	coref	20-32[178_157]
18-46	2724-2729	cells	place[157]	giv[157]	_	_
18-47	2730-2732	in	place[157]	giv[157]	_	_
18-48	2733-2736	the	place[157]|place[158]	giv[157]|new[158]	_	_
18-49	2737-2742	early	place[157]|place[158]	giv[157]|new[158]	_	_
18-50	2743-2751	endosome	place[157]|place[158]	giv[157]|new[158]	_	_
18-51	2752-2753	,	place[157]	giv[157]	_	_
18-52	2754-2757	but	place[157]	giv[157]	_	_
18-53	2758-2761	not	place[157]	giv[157]	_	_
18-54	2762-2770	lysosome	place[157]|abstract	giv[157]|new	_	_
18-55	2771-2772	,	_	_	_	_
18-56	2773-2780	without	_	_	_	_
18-57	2781-2790	requiring	_	_	_	_
18-58	2791-2800	lysosomal	abstract|abstract[161]	new|new[161]	_	_
18-59	2801-2808	enzymes	abstract[161]	new[161]	_	_
18-60	2809-2813	such	abstract[161]	new[161]	_	_
18-61	2814-2816	as	abstract[161]	new[161]	_	_
18-62	2817-2825	MERS-CoV	abstract[161]|abstract	new[161]|giv	_	_
18-63	2826-2827	.	_	_	_	_

#Text=As for IBV , the furin-S2′ site is a determinant of cellular adaptation of the IBV-Beaudette strain .
19-1	2828-2830	As	_	_	_	_
19-2	2831-2834	for	_	_	_	_
19-3	2835-2838	IBV	abstract	giv	coref	20-16
19-4	2839-2840	,	_	_	_	_
19-5	2841-2844	the	abstract[165]	giv[165]	coref	19-9[166_165]
19-6	2845-2854	furin-S2′	abstract|abstract[165]	giv|giv[165]	coref	22-11
19-7	2855-2859	site	abstract[165]	giv[165]	_	_
19-8	2860-2862	is	_	_	_	_
19-9	2863-2864	a	abstract[166]	giv[166]	coref	22-10[190_166]
19-10	2865-2876	determinant	abstract[166]	giv[166]	_	_
19-11	2877-2879	of	abstract[166]	giv[166]	_	_
19-12	2880-2888	cellular	abstract[166]|abstract[167]	giv[166]|new[167]	_	_
19-13	2889-2899	adaptation	abstract[166]|abstract[167]	giv[166]|new[167]	_	_
19-14	2900-2902	of	abstract[166]|abstract[167]	giv[166]|new[167]	_	_
19-15	2903-2906	the	abstract[166]|abstract[167]|abstract[169]	giv[166]|new[167]|giv[169]	coref	20-7[172_169]
19-16	2907-2920	IBV-Beaudette	abstract[166]|abstract[167]|person|abstract[169]	giv[166]|new[167]|new|giv[169]	coref	20-8
19-17	2921-2927	strain	abstract[166]|abstract[167]|abstract[169]	giv[166]|new[167]|giv[169]	_	_
19-18	2928-2929	.	_	_	_	_

#Text=If this motif is lacking , the IBV-Beaudette strain , which is normally the only IBV strain able to adapt to the Vero cell line , can no longer grow in these cells .
20-1	2930-2932	If	_	_	_	_
20-2	2933-2937	this	abstract[170]	new[170]	_	_
20-3	2938-2943	motif	abstract[170]	new[170]	_	_
20-4	2944-2946	is	_	_	_	_
20-5	2947-2954	lacking	_	_	_	_
20-6	2955-2956	,	_	_	_	_
20-7	2957-2960	the	abstract[172]	giv[172]	coref	20-14[174_172]
20-8	2961-2974	IBV-Beaudette	person|abstract[172]	giv|giv[172]	coref	21-14
20-9	2975-2981	strain	abstract[172]	giv[172]	_	_
20-10	2982-2983	,	_	_	_	_
20-11	2984-2989	which	_	_	_	_
20-12	2990-2992	is	_	_	_	_
20-13	2993-3001	normally	_	_	_	_
20-14	3002-3005	the	abstract[174]	giv[174]	coref	21-13[183_174]
20-15	3006-3010	only	abstract[174]	giv[174]	_	_
20-16	3011-3014	IBV	abstract|abstract[174]	giv|giv[174]	coref	21-5
20-17	3015-3021	strain	abstract[174]	giv[174]	_	_
20-18	3022-3026	able	_	_	_	_
20-19	3027-3029	to	_	_	_	_
20-20	3030-3035	adapt	_	_	_	_
20-21	3036-3038	to	_	_	_	_
20-22	3039-3042	the	object[177]	new[177]	_	_
20-23	3043-3047	Vero	person|object[177]	new|new[177]	_	_
20-24	3048-3052	cell	object|object[177]	giv|new[177]	coref	23-8
20-25	3053-3057	line	object[177]	new[177]	_	_
20-26	3058-3059	,	_	_	_	_
20-27	3060-3063	can	_	_	_	_
20-28	3064-3066	no	_	_	_	_
20-29	3067-3073	longer	_	_	_	_
20-30	3074-3078	grow	_	_	_	_
20-31	3079-3081	in	_	_	_	_
20-32	3082-3087	these	place[178]	giv[178]	_	_
20-33	3088-3093	cells	place[178]	giv[178]	_	_
20-34	3094-3095	.	_	_	_	_

#Text=Most basic research on IBV performed to date has been based on the IBV-Beaudette strain ; therefore , much remains unknown about the pathogenic mechanism of QX-type IBV .
21-1	3096-3100	Most	abstract[179]	new[179]	coref	25-19[0_179]
21-2	3101-3106	basic	abstract[179]	new[179]	_	_
21-3	3107-3115	research	abstract[179]	new[179]	_	_
21-4	3116-3118	on	abstract[179]	new[179]	_	_
21-5	3119-3122	IBV	abstract[179]|abstract	new[179]|giv	coref	22-22[193_0]
21-6	3123-3132	performed	_	_	_	_
21-7	3133-3135	to	_	_	_	_
21-8	3136-3140	date	time	new	_	_
21-9	3141-3144	has	_	_	_	_
21-10	3145-3149	been	_	_	_	_
21-11	3150-3155	based	_	_	_	_
21-12	3156-3158	on	_	_	_	_
21-13	3159-3162	the	abstract[183]	giv[183]	coref	25-21[207_183]
21-14	3163-3176	IBV-Beaudette	person|abstract[183]	giv|giv[183]	coref	25-22
21-15	3177-3183	strain	abstract[183]	giv[183]	_	_
21-16	3184-3185	;	_	_	_	_
21-17	3186-3195	therefore	_	_	_	_
21-18	3196-3197	,	_	_	_	_
21-19	3198-3202	much	_	_	_	_
21-20	3203-3210	remains	_	_	_	_
21-21	3211-3218	unknown	_	_	_	_
21-22	3219-3224	about	_	_	_	_
21-23	3225-3228	the	abstract[184]	new[184]	_	_
21-24	3229-3239	pathogenic	abstract[184]	new[184]	_	_
21-25	3240-3249	mechanism	abstract[184]	new[184]	_	_
21-26	3250-3252	of	abstract[184]	new[184]	_	_
21-27	3253-3260	QX-type	abstract[184]|substance[185]	new[184]|giv[185]	coref	22-7[188_185]
21-28	3261-3264	IBV	abstract[184]|substance[185]	new[184]|giv[185]	_	_
21-29	3265-3266	.	_	_	_	_

#Text=Here , we rescued a mutant QX-type IBV with the furin-S2′ site and compared the pathogenicity of the mutant IBV with its parental virus .
22-1	3267-3271	Here	_	_	_	_
22-2	3272-3273	,	_	_	_	_
22-3	3274-3276	we	person	acc	ana	23-1
22-4	3277-3284	rescued	_	_	_	_
22-5	3285-3286	a	person[187]	new[187]	_	_
22-6	3287-3293	mutant	person[187]	new[187]	_	_
22-7	3294-3301	QX-type	abstract[188]	giv[188]	coref	22-18[192_188]
22-8	3302-3305	IBV	abstract[188]	giv[188]	_	_
22-9	3306-3310	with	_	_	_	_
22-10	3311-3314	the	organization[190]	giv[190]	_	_
22-11	3315-3324	furin-S2′	abstract|organization[190]	giv|giv[190]	_	_
22-12	3325-3329	site	organization[190]	giv[190]	_	_
22-13	3330-3333	and	_	_	_	_
22-14	3334-3342	compared	_	_	_	_
22-15	3343-3346	the	abstract[191]	new[191]	_	_
22-16	3347-3360	pathogenicity	abstract[191]	new[191]	_	_
22-17	3361-3363	of	abstract[191]	new[191]	_	_
22-18	3364-3367	the	abstract[191]|abstract[192]	new[191]|giv[192]	coref	25-7[203_192]
22-19	3368-3374	mutant	abstract[191]|abstract[192]	new[191]|giv[192]	_	_
22-20	3375-3378	IBV	abstract[191]|abstract[192]	new[191]|giv[192]	_	_
22-21	3379-3383	with	abstract[191]|abstract[192]	new[191]|giv[192]	_	_
22-22	3384-3387	its	abstract[191]|abstract[192]|abstract[193]	new[191]|giv[192]|giv[193]	_	_
22-23	3388-3396	parental	abstract[191]|abstract[192]|abstract[193]	new[191]|giv[192]|giv[193]	_	_
22-24	3397-3402	virus	abstract[191]|abstract[192]|abstract[193]	new[191]|giv[192]|giv[193]	_	_
22-25	3403-3404	.	_	_	_	_

#Text=We also further investigated the tissue and cell tropism .
23-1	3405-3407	We	person	giv	ana	24-3
23-2	3408-3412	also	_	_	_	_
23-3	3413-3420	further	_	_	_	_
23-4	3421-3433	investigated	_	_	_	_
23-5	3434-3437	the	object[195]	new[195]	_	_
23-6	3438-3444	tissue	object[195]	new[195]	_	_
23-7	3445-3448	and	_	_	_	_
23-8	3449-3453	cell	place|abstract[197]	giv|new[197]	_	_
23-9	3454-3461	tropism	abstract[197]	new[197]	_	_
23-10	3462-3463	.	_	_	_	_

#Text=Finally , we clarified the biological significance with an immunoprotection experiment .
24-1	3464-3471	Finally	_	_	_	_
24-2	3472-3473	,	_	_	_	_
24-3	3474-3476	we	person	giv	_	_
24-4	3477-3486	clarified	_	_	_	_
24-5	3487-3490	the	abstract[199]	new[199]	_	_
24-6	3491-3501	biological	abstract[199]	new[199]	_	_
24-7	3502-3514	significance	abstract[199]	new[199]	_	_
24-8	3515-3519	with	abstract[199]	new[199]	_	_
24-9	3520-3522	an	abstract[199]|abstract[200]	new[199]|new[200]	_	_
24-10	3523-3539	immunoprotection	abstract[199]|abstract[200]	new[199]|new[200]	_	_
24-11	3540-3550	experiment	abstract[199]|abstract[200]	new[199]|new[200]	_	_
24-12	3551-3552	.	_	_	_	_

#Text=The function of S protein in QX-type IBV was demonstrated , which is more valuable for poultry than research about the IBV-Beaudette strain .
25-1	3553-3556	The	abstract[201]	new[201]	_	_
25-2	3557-3565	function	abstract[201]	new[201]	_	_
25-3	3566-3568	of	abstract[201]	new[201]	_	_
25-4	3569-3570	S	abstract[201]|substance[202]	new[201]|giv[202]	_	_
25-5	3571-3578	protein	abstract[201]|substance[202]	new[201]|giv[202]	_	_
25-6	3579-3581	in	abstract[201]|substance[202]	new[201]|giv[202]	_	_
25-7	3582-3589	QX-type	abstract[201]|substance[202]|abstract[203]	new[201]|giv[202]|giv[203]	_	_
25-8	3590-3593	IBV	abstract[201]|substance[202]|abstract[203]	new[201]|giv[202]|giv[203]	_	_
25-9	3594-3597	was	_	_	_	_
25-10	3598-3610	demonstrated	_	_	_	_
25-11	3611-3612	,	_	_	_	_
25-12	3613-3618	which	_	_	_	_
25-13	3619-3621	is	_	_	_	_
25-14	3622-3626	more	_	_	_	_
25-15	3627-3635	valuable	_	_	_	_
25-16	3636-3639	for	_	_	_	_
25-17	3640-3647	poultry	animal[204]	giv[204]	_	_
25-18	3648-3652	than	animal[204]	giv[204]	_	_
25-19	3653-3661	research	animal[204]|abstract	giv[204]|giv	_	_
25-20	3662-3667	about	animal[204]	giv[204]	_	_
25-21	3668-3671	the	animal[204]|abstract[207]	giv[204]|giv[207]	_	_
25-22	3672-3685	IBV-Beaudette	animal[204]|person|abstract[207]	giv[204]|giv|giv[207]	_	_
25-23	3686-3692	strain	animal[204]|abstract[207]	giv[204]|giv[207]	_	_
25-24	3693-3694	.	_	_	_	_
